The low consistency in BRAF mutation patterns among MPM lesions from the same patients arises the practical question on how cases with coexistence of BRAFwild-type and BRAFmutant primary melanomas (and, to a less extent, those carrying different BRAF variants - which may present a different degree of responsiveness to BRAF inhibitors) should be molecularly classified. This evidence concerns the gene BRAF and melanoma.